Infectious Disease Reports,
Journal Year:
2023,
Volume and Issue:
15(4), P. 386 - 391
Published: July 10, 2023
Intraparenchymal
lung
abscess
development
associated
with
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
infection
is
a
rare
complication,
only
half
dozen
primary
cases
having
been
reported
in
the
literature.
We
present
case
of
patient
Waldenström's
macroglobulinemia
who
developed
subsequent
to
SARS-CoV-2
infection.
63-year-old
male
and
history
cavitating
intraparenchymal
an
air-fluid
level
his
right
lower
lobe
two
weeks
following
admission
hospital.
The
became
septic
failure
requiring
mechanical
ventilation
intensive
care.
He
was
managed
broad-spectrum
antibiotic
therapy
aspiration
drainage,
but
unfortunately
due
clinical
condition
died
20
days
after
initial
admission.
patients
COVID-19,
although
rare,
can
be
quite
compromising
even
prove
fatal,
especially
immunocompromised
patients.
Clinicians
should
aware
this
potential
complication.
Metabolites,
Journal Year:
2023,
Volume and Issue:
13(2), P. 309 - 309
Published: Feb. 20, 2023
The
nucleoside
analog
β-D-N4-hydroxycytidine
is
the
active
metabolite
of
prodrug
molnupiravir
and
accepted
as
an
efficient
drug
against
COVID-19.
Molnupiravir
targets
RNA-dependent
RNA
polymerase
(RdRp)
enzyme,
which
responsible
for
replicating
viral
genome
during
replication
process
certain
types
viruses.
It
works
by
disrupting
normal
function
RdRp
causing
it
to
make
mistakes
genome.
These
can
prevent
from
being
transcribed,
converted
into
a
complementary
DNA
template,
translated,
or
functional
protein.
By
these
crucial
steps
in
process,
effectively
inhibit
virus
reduce
its
ability
cause
disease.
This
review
article
sheds
light
on
impact
SARS-CoV-2
variants
concern,
such
delta,
omicron,
hybrid/recombinant
variants.
detailed
mechanism
molecular
interactions
using
docking
dynamics
have
also
been
covered.
safety
tolerability
patients
with
comorbidities
emphasized.
Vaccines,
Journal Year:
2023,
Volume and Issue:
11(3), P. 555 - 555
Published: Feb. 27, 2023
Coronavirus
disease
2019
(COVID-19)
infection
is
currently
a
great
cause
of
concern
for
the
healthcare
sector
around
globe.
SARS-CoV-2
an
RNA
virus
that
causes
serious
associated
with
numerous
adverse
effects
and
multiple
complications
different
organs
systems
during
its
pathogenic
cycle
in
humans.
Individuals
affected
by
COVID-19,
especially
elderly
populations
immunocompromised
people,
are
greatly
vulnerable
to
opportunistic
fungal
pathogens.
Aspergillosis,
invasive
candidiasis,
mucormycosis
widespread
coinfections
COVID-19
patients.
Other
infections
rare
but
exhibiting
increased
incidence
current
scenario
include
caused
Pneumocystis
jirovecii,
Histoplasma
sp.,
Cryptococcus
etc.
By
producing
virulent
spores,
these
pathogens
increase
severity
morbidity
fatality
rates
patients
globally.
These
generally
occur
recovering
from
infection,
resulting
rehospitalization.
Older
individuals
at
higher
risk
developing
infections.
This
review
focuses
on
understanding
prevalent
patients,
people.
We
have
also
highlighted
important
preventive
methods,
diagnostic
approaches,
prophylactic
measures
The European Physical Journal Plus,
Journal Year:
2024,
Volume and Issue:
139(11)
Published: Nov. 28, 2024
Abstract
In
this
paper,
we
present
a
mathematical
model
to
analyze
the
dynamics
of
leptospirosis
and
COVID-19
co-infection.
The
used
actual
data,
estimation
parameters
via
MLE
method
is
performed,
which
includes
rates
disease
transmission,
progression
disease,
disease-related
death,
recovery
for
each
their
Key
parameters:
$$\beta
_1$$
β1
,
_2$$
2
$$\phi
ϕ
$$\mu
_c$$
μc
are
characterize
co-infection
burden
COVID-19.
results
reveal
notable
contrast
in
transmission
clinical
outcomes
between
two
diseases,
with
demonstrating
higher
rate
increased
morbidity.
Co-infections
showed
more
severe
outcomes,
mortality
delayed
than
single
infections.
These
findings
highlight
importance
targeted
public
health
strategies
managing
co-infected
populations.
International Journal of General Medicine,
Journal Year:
2023,
Volume and Issue:
Volume 16, P. 1479 - 1490
Published: April 1, 2023
Introduction:
Many
with
post-acute
SARS-CoV-2
(PASC)
have
persistent
symptoms
impacting
physical
and
cognitive
function,
decreased
health
health-related
life
quality.
Monoclonal
antibody
(mAb)
treatment
was
available
to
acutely
infected
patients
which
might
improve
these
outcomes.
Purpose:
To
compare
patient
perception
of
PASC
for
those
receiving
bamlanivimab
or
casirivimab
imdevimab
(mAbs)
not
this
(non-mAbs).
changes
between
groups
in
symptoms,
function
quality
over
a
6-month
follow-up.
Patients
Methods:
Consented
adults
>
28
days
post-infection
positive
qPCR
antigen
test
infection
March
2020
July
2022
were
enrolled.
This
prospective,
repeated
measure
observational
study
reports
baseline
through
Extensive
sociodemographic
data,
detailed
medical
history,
COVID-19
symptom
standardized
measures
well-being,
depression,
anxiety,
stigma,
cognition,
assessment,
distress,
status
collected.
Results:
323
participants
[101
mAb,
221
non-mAb,
52.7±
15.5
years,
47.7%
male,
body
mass
index
(BMI)
31.4±
8.4]
analyzed.
Fewer
at
reported
mAb
versus
non-mAb
(1.06±
1.31
vs
1.78±
2.15,
respectively
p=0.0177)
6
months:
(0.911±
1.276
vs.1.75±
2.22
p=0.0427).
Both
showed
significant
within-group
decreases
number
(52
21
126
63
non-mAb)
burden
(p=0.0088
p<
0.00001
non-mAb).
had
significantly
shorter
infection-to-baseline
interval
(days)
(120.4±
55.3
194.0±
89.3
0.00001);
less
frequent
history
myocardial
infarction
(0.0
3.9%,
p=0.0464);
headache
(2.0%
vs.11.8%,
p=0.0046),
rash
(3.1%
9.9%,
p=0.0377),
miscellaneous
muscle
complaints
12.3%,
p=0.0035),
plus
better
mood.
(2.2%
13.2%,
p=0.0390).
Conclusion:
treated
reduced
consistently
fewer
than
all
time
points
despite
since
acute
illness.
statistically
decrease
by
visit
no
differences
them
Keywords:
monoclonal
antibodies,
patient-reported
outcomes,
burden,
recovery,
Nanotechnology-based
vaccines
are
a
promising
area
of
research
that
offers
numerous
advantages
over
traditional
vaccines.
They
have
the
potential
to
provide
enhanced
immunogenicity,
reduced
side
effects,
improved
stability,
and
multifunctional
capabilities.
Nanoparticle
can
be
administered
through
various
routes,
including
intramuscular
injection,
subcutaneous
intradermal
oral
delivery,
nasal
topical
application.
However,
large-scale
manufacturing
uniformity
in
regulatory
guidelines
major
challenges
associated
with
nanoparticle-based
needs
addressed.
Despite
these
challenges,
development
nanotechnology-based
an
exciting
opportunity
improve
vaccine
efficacy
accessibility.
Science Progress,
Journal Year:
2023,
Volume and Issue:
106(4)
Published: Oct. 1, 2023
Secondary
infections
can
occur
during
or
after
the
treatment
of
an
initial
infection.
Glucocorticoids
may
decrease
mortality
in
patients
with
severe
COVID-19;
however,
risk
secondary
infection
is
not
well
described.
Our
primary
objective
was
to
investigate
among
critically
ill
COVID-19
treated
glucocorticoids.
We
examined
being
intensive
care
unit
at
two
academic
medical
centers
from
1
7/2020.
One
hundred-seven
were
included.
Of
these,
31
received
steroids
and
76
did
not.
Analysis
larger
cohort
performed
followed
by
a
matched
pairs
analysis
22
steroid
non-steroid
patients.
seen
14
(45.2%)
receiving
compared
35(46.1%)
(p
=
0.968).
most
frequently
encountered
respiratory
tract.
Escherichia
coli
Staphylococcus
aureus
identified
organisms.
Mortality
16.1%
steroid-treated
group
23.7%
control
0.388).
After
performing
multivariable
logistic
regression
there
no
significant
difference
between
receipt.
common
COVID-19,
but
incidence
significantly
impacted
treatment.
